EP
Elkhorn Partners’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $195K | Sell |
4,000
-200
| -5% | -$9.73K | 0.14% | 20 |
|
|
2025
Q1 | $143K | Buy |
4,200
+400
| +11% | +$13.6K | 0.09% | 21 |
|
|
2024
Q4 | $150K | Buy |
3,800
+700
| +23% | +$27.6K | 0.1% | 22 |
|
|
2024
Q3 | $146K | Buy |
3,100
+2,100
| +210% | +$98.9K | 0.09% | 23 |
|
|
2024
Q2 | $54K | Buy |
+1,000
| New | +$54K | 0.04% | 35 |
|
|
2023
Q4 | – | Sell |
-250
| Closed | -$11K | – | 49 |
|
|
2023
Q3 | $11K | Buy |
250
+220
| +733% | +$9.68K | 0.01% | 46 |
|
|
2023
Q2 | $2K | Sell |
30
-570
| -95% | -$38K | ﹤0.01% | 48 |
|
|
2023
Q1 | $27K | Sell |
600
-750
| -56% | -$33.8K | 0.02% | 41 |
|
|
2022
Q4 | $55K | Buy |
+1,350
| New | +$55K | 0.04% | 29 |
|
|
2022
Q2 | – | Sell |
-550
| Closed | -$35K | – | 49 |
|
|
2022
Q1 | $35K | Buy |
550
+200
| +57% | +$12.7K | 0.02% | 39 |
|
|
2021
Q4 | $27K | Buy |
350
+225
| +180% | +$17.4K | 0.02% | 36 |
|
|
2021
Q3 | $14K | Hold |
125
| – | – | 0.01% | 40 |
|
|
2021
Q2 | $20K | Buy |
+125
| New | +$20K | 0.01% | 37 |
|